Cerebrotendinous Xanthomatosis Therapeutics Market Size, Share, and Industry Analysis, By Product (CTEXLI (Chenodiol), and Others), By Route of Administration (Oral and Parenteral), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2026-2034

The global cerebrotendinous xanthomatosis therapeutics market is witnessing substantial growth due to rising investment in research and development to advance treatments of ultra-rare diseases. Additionally, government support is also expected to drive the market's growth due to fast-track approvals and government funding.

Cerebrotendinous xanthomatosis (CTX) is a rare autosomal recessive disorder caused by mutations in the sterol 27-hydroxylase gene (CYP27A1). Due to the deficiency of 27-hydroxylase, the synthesis of bile acids from cholesterol is impaired, and excessive cholestanol accumulates in various tissues, such as the central nervous system, tendons, and lenses. Patients with CTX typically manifest intellectual decline, pyramidal tract symptoms, cerebellar symptoms, tendon xanthomas, juvenile cataracts, neonatal jaundice, chronic diarrhea, osteoporosis, and premature cardiovascular disease. 

• For instance, in February 2024, Vivet Therapeutics received USD 5.3 million from the French government to advance the development of a gene therapy for treating cerebrotendinous xanthomatosis (CTX), a rare neurodegenerative disease. 

Cerebrotendinous Xanthomatosis Therapeutics Market Driver

Rise in Precise Diagnostics of Cerebrotendinous Xanthomatosis, accompanied by Government Support to Drive Market Growth

Earlier, the rare disease was often misdiagnosed with other conditions due to nonspecific symptoms. However, with the increasing knowledge base of the disease, better understanding of biomarkers and genetic testing, diagnosis has improved. These factors offer a market expansion opportunity.

The rising investment and government support are also expected to further the market expansion, various incentivized schemes, and other assistance help manage rare diseases.

• For instance, in September 2024, the European Commission granted orphan drug designation to the gene therapy product VTX-806 for treating cerebrotendinous xanthomatosis. This designation grants benefits such as tax credits for qualified clinical trials, exemption from user fees, and potential seven years of market exclusivity after approval. Such developments are expected to drive the market growth further. 

Estimated Incidence of Per Case in Total Population for Cerebrotendinous Xanthomatosis, By Geographic Regions 

DynaMed reported that one case was found for every 73,873 people in South Asia.

Cerebrotendinous Xanthomatosis Therapeutics Market Restraint

Excessive Pricing for Treating Rare Diseases Poses a Significant Factor Impeding Market Growth

The prices for treatment of rare diseases, such as cerebrotendinous xanthomatosis, are exceptionally high. Additionally, a few companies are exploiting their market exclusivity patents to increase prices further. Such factors led to high prices and impede the market growth potential. Numerous lawsuits were filed against these companies in response to such high prices to compel them to lower prices.

• For instance, in July 2021, the Dutch Authority for Consumers and Markets (ACM) imposed a fine of USD 21.03 million on drug manufacturer Leadiant for excessive Pricing of their orphan drug CDCA-Leadiant, which is used for the treatment of the rare genetic metabolic disorder cerebrotendinous xanthomatosis (CTX).

Cerebrotendinous Xanthomatosis Therapeutics Market Opportunity

Focus On Obtaining Regulatory Approvals by Different Regulatory Bodies Offers Lucrative Opportunity for Market Expansion in Key Countries

There were no targeted therapies for the treatment of cerebrotendinous xanthomatosis until now. However, the targeted treatment was launched after relentless research and development initiatives by Mirum Pharmaceuticals in the U.S. This led to approval of the first therapy for cerebrotendinous xanthomatosis by the U.S. FDA.

Regulatory approvals from other regulatory bodies, such as the European Commission and the National Medical Products Administration, offer further market expansion opportunities in emerging economies. 

Key Insights

The report covers the following key insights:

• Epidemiology of Cerebrotendinous Xanthomatosis, Key Countries, 2024
• Reimbursement Scenarios- By Key Countries/ Regions
• Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
• Pipeline Analysis
• Therapeutic Alternatives in the Market

Segmentation

Analysis by Product

By product, the market is divided into CTEXLI (chenodiol) and others.

CTEXLI (Chenodiol) is expected to hold a dominant position in the global cerebrotendinous xanthomatosis therapeutics market based on product. The high market share of the drug is due to its approval in key markets such as North America. 

• For instance, in February 2025, Mirum Pharmaceuticals, Inc. received the U.S. FDA's approval for CTEXLI (Chenodiol) tablets for treating adults with cerebrotendinous xanthomatosis (CTX). CTEXLI is the first and only treatment approved for this rare, progressive, and debilitating disease. These factors are expected to fuel the market growth. 

Analysis by Route of Administration

By route of administration, the market is divided into oral and parenteral.

The oral segment is expected to hold a considerable share. The oral segment's high market share is due to the presence of the sole drug approved for the treatment by the U.S. FDA.

• For instance, the U.S. FDA label for Ctexil, updated in February 2025, reported that the recommended dosage of CTEXLI is 250 mg administered orally three times daily.

 Analysis by Distribution Channel

By distribution channel, the market is divided into hospital pharmacies, drug stores & retail pharmacies, and online pharmacies.

Hospital pharmacies are expected to hold a significant market share. The high market share of hospital pharmacies is expected to hold a considerable market share. The high market share of hospital pharmacies is due to various collaborations between the government, hospital pharmacies, and pharmaceutical companies to meet the clinical needs of patients with rare diseases.

• For instance, in October 2024, Alnylam Pharmaceuticals, Inc., collaborated with Pharmacy Innovation Network (PIN) to provide better care for patients with rare diseases. The collaboration equipped pharmacists with cutting-edge knowledge and best practices for rare disease management.

Regional Analysis

By region, the market is divided into North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America.

Request for Customization   to gain extensive market insights.

North America accounted for the largest share of the global cerebrotendinous xanthomatosis therapeutics market in 2024. The growth of the market in the region is attributed to strategic activities such as acquisitions by established players to expand their product offering in the market. 

• For instance, in July 2023, Mirum Pharmaceuticals, Inc. acquired Travere Therapeutics, Inc. The acquisition provided Travere's bile acid product portfolio, including Cholbam (cholic acid) and Chenodal (chenodiol). Chenodal, indicated for the treatment of radiolucent stones in the gallbladder, is also under Phase 3 clinical evaluation for cerebrotendinous xanthomatosis (CTX). Additionally, regulatory approvals from governing bodies are expected to drive the market further.

Europe is expected to hold a considerable market share in the forecast period of the global cerebrotendinous xanthomatosis market. The region's high market share is due to increasing investment in research initiatives in the region. Additionally, various key companies are focusing on conferences and poster presentations to attract potential investors and facilitate new product launches.

• For instance, in February 2024, Vivet Therapeutics presented three posters on the cerebrotendinous xanthomatosis program and novel AAV gene delivery platform at the European Society of Gene and Cell Therapy annual congress 2024. Such developments are expected to offer lucrative growth opportunities in the region.

Asia Pacific is expected to grow with a significant CAGR during the forecast period. The regional growth is attributed to the presence of support groups and rising awareness of rare diseases due to various conferences being held in the region.

• For instance, in September 2025, the International Workshop series is scheduled in Kyoto, Japan, and is dedicated to cerebrotendinous xanthomatosis. Such developments are expected to raise awareness of the rare disease and assist in developing the global cerebrotendinous xanthomatosis therapeutics market.

Key Players Covered

The global cerebrotendinous xanthomatosis therapeutics market is consolidated with the presence of a few emerging companies. The report includes the profiles of the following key players:

• Mirum Pharmaceuticals, Inc. (U.S.)
• Travere Therapeutics, Inc. (U.S.)
• Leadiant Biosciences Ltd. (U.K.)
• Vivet Therapeutics (Paris, France)

Key Industry Developments

• In February 2025, Genomenon, Inc., partnered with Mirum Pharmaceuticals, Inc. to improve the awareness and diagnosis of Cerebrotendinous Xanthomatosis (CTX). The collaboration focused on CYP27A1 gene variants, making genetic data accessible to testing laboratories worldwide.
• In November 2024, Vivet Therapeutics presented key pre-clinical findings for VTX-806, its gene therapy program for the treatment of Cerebrotendinous Xanthomatosis (CTX), at The Liver Meeting presented by the American Association for the Study of Liver Diseases (AASLD), in the U.S.
• In January 2022, the Pharmaceutical Accountability Foundation resumed supplying Dutch patients with the rare disease Cerebrotendinous Xanthomatosis (CTX) with pharmacy-compounded chenodeoxycholic acid.